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Abstract
Chronic bronchopulmonary bacterial infections remain the most common cause of morbidity and mortality
among patients with cystic fibrosis (CF). Recent community sequencing work has now shown that the bacterial
community in the CF lung is polymicrobial. Identifying bacteria in the CF lung through sequencing can be costly
and is not practical for many laboratories. Molecular techniques such as terminal restriction fragment length poly-
morphism or amplicon length heterogeneity–polymerase chain reaction (LH-PCR) can provide many laboratories
with the ability to study CF bacterial communities without costly sequencing. The aim of this study was to deter-
mine if the use of LH-PCR with multiple hypervariable regions of the 16S rRNA gene could be used to identify
organisms found in sputum DNA. This work also determined if LH-PCR could be used to observe the dynamics
of lung infections over a period of time. Nineteen samples were analysed with the V1 and the V1_V2 region of
the 16S rRNA gene. Based on the amplicon size present in the V1_V2 region, Pseudomonas aeruginosa was con-
firmed to be in all 19 samples obtained from the patients. The V1 region provided a higher power of discrimi-
nation between bacterial profiles of patients. Both regions were able to identify trends in the bacterial population
over a period of time. LH profiles showed that the CF lung community is dynamic and that changes in the com-
munity may in part be driven by the patient’s antibiotic treatment. LH-PCR is a tool that is well suited for study-
ing bacterial communities and their dynamics.
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Introduction
Cystic fibrosis (CF) is an autorecessive disease
affecting one in 3,500 Caucasian live births in the
USA.1 CF results from a mutation in the gene that
encodes the CF transmembrane conductance regu-
lator (CFTR) protein.2,3 A defect in the CFTR
protein leads to a malfunctioning cyclic
AMP-activated chloride channel in secretory
epithelia.4 This defect in the lung leads to the
inability to secrete chloride and to the excess
re-absorption of sodium.4 Thus, there is decreased
fluid secretion and the mucus becomes immobilised
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and adheres to the epithelial cells. Overproduction
of mucus in the airway results in congestion of the
respiratory tract and increases susceptibility to
bronchopulmonary infection. CF patients often
suffer from infections with Staphylococcus aureus,
Haemophilus influenzae, Pseudomonas aeruginosa and
Burkholderia cenocepacia.5 These chronic infections
by highly adapted lung microbes cause inflam-
mation and, eventually, lung damage; therefore,
lung disease is the major cause of morbidity and
mortality among these patients.6,7
It has also been estimated that less than 1 per
cent of eubacteria in the environment can be cul-
tured.8,9 Thus, these identification methods will fail
to detect all pathogens that might be causing the
lung infection. Fortunately, with the advent of
molecular techniques, culturing for identification
purposes can be circumvented.10 Recent molecular
studies using terminal restriction fragment length
analysis and sequencing have shown that the lung
community is complex. Achromobacter (Alcaligenes)
xylosoxidans, Rhodotorula mucilaginosa, Abiotrophia
spp, Bacteroides gracilis, Eubacterium brachy,
Mycobacterium mucilaginosus, Mycoplasma salivarium,
Porphyromonas salivae, Ralstonia spp, Staphylococcus
hominis, Streptococcus anginosus, Treponema vincentii,
Veillonella spp, Burkholderia gladioli, Stenotrophomonas
maltophilia and Pandoraea atypical have all been
demonstrated to be members of this polymicrobial
infection.11–18
Amplicon length heterogeneity–polymerase
chain reaction (LH-PCR) is another molecular
method that has been used to study various diverse
microbial communities,19,20 including those of CF
sputum.18 LH-PCR utilises the 16S rRNA mole-
cular marker to analyse microbial populations.20–22
The sequence and length of the variable regions
within the 16S rRNA gene are often used to deter-
mine phylogeny.23 It should be noted that some
bacteria have multiple copies of the 16S rRNA
gene, which can show intragenomic heterogeneity
in sequence and gene length.23 This variation is
unlikely to have an effect on classification at the
genus and species level, and the marker is routinely
used for identification.24 Identification based on
length variation in the hypervariable regions of the
gene is exploited by LH-PCR. In this technique,
forward and reverse primers bind to the conserved
regions of the 16S rRNA gene and then amplify
the varying lengths seen in the hypervariable
regions. LH-PCR has proven to be a robust, time-
efficient and reproducible method.20,21,25 The main
advantages of LH-PCR are that it surveys relative
gene frequencies within complex mixtures of
DNA, is reproducible, requires small sample sizes
and can be performed with many samples simul-
taneously.20,25 Furthermore, some of the size classes
emerging from LH-PCR analyses can be related at
the genus level to archived database sequences.20
Overall, the attributes of LH-PCR make it useful
for quick assessment of the diversity of microbial
communities for comparative purposes.20
Prior studies have shown that LH-PCR and the
hypervariable regions 1 and 2 (V1_V2) of the 16S
rRNA gene can be used to detect eubacteria in
sputum from CF patients.18,26 The technique had
limited efficacy when determining overall diversity
and attaining organism identification, and it was
concluded that the small differences in amplicon
lengths generated from the organisms were at
fault.18 In this study, community profiles of CF
sputa were obtained using two regions of the 16S
rRNA gene (hypervariable region 1 [V1] and
V1_V2). Bacterial identification based on amplicon
length was attempted using a computer program,
AmpliQue´, which determined the theoretical V1
and V1_V2 fragment lengths for known organisms.
Community profiles and identification were ana-
lysed using each region separately and combined to
determine if a combinatorial approach to
LH-PCR: 1) could provide a more detailed analysis
of the bacterial community in the CF lung and 2)
could be used to observe the dynamics of this com-
munity over a period of time. Our work has shown
that the V1 region provides a more detailed com-
munity profile, which leads to a higher power of
discrimination between profiles than the V1_V2
region. The LH analyses provided snapshots of the
CF bacterial communities; however, the analyses
are limited by their ability to identify community
members with the V1 or V1_V2 regions separately
or combined. In addition, through the comparisons
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of V1_V2 or V1 LH profiles over time, it was
established that the CF lung community is not only
diverse, but also dynamic.
Materials and methods
Sample collection
Nineteen sputum samples were obtained from CF
patients attending the University of Miami Adult
CF Clinic (Miami, FL). Samples are referred to by
UM followed by a letter. The study was carried out
in accordance with the Declaration of Helsinki
(2000) of the World Medical Association and was
approved by the appropriate institutional review
board (FIU IRB approval # 033004-02).
Appropriate consent was obtained from human
subjects. All 19 expectorated sputum samples were
frozen at 2208C prior to DNA extraction.
Sputum was liquefied using the method of Reischl
et al.27 and the metagenomic DNA was extracted
and cleaned using the GeneClean Spin Kit
(Qbiogene, Irvine, CA, USA) according to the
manufacturer’s protocol. The eluted DNA was
quantified and diluted to 10 ng/ml and refrigerated
at 48C until further use.
Control bacteria isolates
Standard DNA manipulations were used to extract
chromosomal DNA from CF-related pathogens: P.
aeruginosa strains PAO1 and PA14 (burn wound iso-
lates) and four additional P. aeruginosa strains isolated
from CF,28 B. cenocepacia (ATCC BAA-246; CF
isolate), S. aureus (ATCC 12600; pleural fluid isolate)
and S. maltophilia (ATCC 17672; sputum isolate),
were used as controls in the LH-PCR experiments.
LH-PCR
The metagenomic DNA derived from the extracted
sputum samples were amplified in triplicate using
eubacterial primers for the 16S rRNA gene. The
V1_V2 region of the 16S rRNA gene were ampli-
fied using 27F-6FAM forward primer (50 – 6FAM
– AGA GTT TGATCM TGG – 30) and the 355R
reverse primer (50 – GCT GCC TCC CGT AGG
AGT – 30).29 The V1 region was amplified using
fluorescent primer P1F-6FAM (50 – 6FAM – GCG
GCG TGC CTA ATA CAT GC – 30) and reverse
primer P2R (50 – TTC CCC ACG CGT TAC
TCA CC – 30).29,30 All forward primers were fluor-
escently labelled with 6-FAMTM (Integrated DNA
Technologies, Shokie, IL, USA). The final V1_V2
PCR reaction mixture was composed of: 1X PCR
buffer (supplied with the enzyme by Applied
Biosystems, Foster City, CA, USA), 2.5 mM MgCl2,
0.25 mM dNTPs, 0.5 mM forward and reverse
primers, 0.1 per cent bovine serum albumin (BSA),
0.025 U of AmpliTaq Gold LD DNA polymerseTM
(Applied Biosystems) and diethylpyrocarbonate
(DEPC) water for a final volume of 20 ml. A half a
nanogram per microlitre of DNA template was
added per reaction. The following parameters were
used to amplify the selected fragments on an MJ
Research Peltier Thermal Cycler 200 (Waltham,
MA, USA): initial denaturation at 958C for 11
minutes, 25 cycles of denaturation at 958C, anneal-
ing at 558C and extension at 728C, each for 1
minute, and a final elongation at 728C for 10
minutes. A negative control containing water was
amplified for every PCR master mix to check for
contamination. Agarose gel electrophoresis was run
to confirm the success of amplification.
LH-PCR analysis
LH-PCR analysis was performed by the Forensic
DNA Profiling Facility (Florida International
University, Miami, FL, USA). The PCR products
for the three replicate reactions were detected using
the ABI Prism 310 Genetic Analyzer (Applied
Biosystems). A formamide-size standard mix was
prepared using a 96:1 ratio of Hi-DiTM (highly
deionised) formamide and GeneScanTM 500
ROXTM internal standard (Applied Biosystems).
Each PCR product was denatured by adding
0.50 ml to 9.5 ml of the formamide-size standard
mix for 2 minutes at 958C and snap cooling for
5 minutes on ice. Each sample was run for 28
minutes on the ABI Prism 310. Fragments were
separated by capillary electrophoresis using polymer
POP-4, matrix DS-3O_6FAM_HEX_NED_ROX
and filter D (Applied Biosystems).
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Electropherogram analysis
The output was collected and analysed using
GeneMapperw Software Version 3.7 (Applied
Biosystems) and Microsoft Excel (Microsoft,
Redmond, WA, USA). The ABI PrismTM
Genotyper software analysis parameters were set to
the local Southern Size calling, no correction, and
the minimum noise threshold was set at 70 fluor-
escent units.21 For V1_V2, amplicons were called if
between 300 and 400 base pairs (bp). Amplicons
for V1 region were between 60 and 120 bp.
Statistical analysis
Data were imported into MS Excel (Microsoft), to
determine mean relative ratios for each triplicate
PCR reaction. The normalised data for each
sample were exported into PRIMER 5 statistical
software for further analyses (PRIMER E Ltd.,
Plymouth Marine Laboratory, Plymouth, UK).
The Bray–Curtis similarity index and non-metric
multi-dimensional scaling (MDS) were used to
compare sample data between patients and patient
profiles over time.31,32
Presumptive identity analysis
GeneScanTM 500 ROXTM internal standard was
used to determine amplicons sites in bp. Several
approaches were used presumptively to identify an
organism in the CF community based upon the
length of the amplicon generated. Chromosomal
DNA from isolates of B. cenocepacia,
Staphylococcus aureus, Stenotrophomonas maltophilia
and P. aeruginosa were used to determine the exper-
imental amplicon length for the V1_V2 and V1
regions. Next, in silico analysis was performed, in
which the expected amplicon length was deter-
mined based on where the primers of interest
would theoretically bind to the published sequence.
Lastly, the lengths of the expected amplicons for all
bacteria were determined using AmpliQue´, a
newly-designed bioinformatics program.29,33 The
Perl scripts are available at http://biorg.cs.fiu.edu/
AmpliQue/. AmpliQue´ uses the 16S rRNA
sequences downloaded from the Ribosomal
Database Project II (Release 9.60). It takes a
forward and a reverse primer (both of which may
be potentially degenerate) as input. The stringency
of the primer binding can be set in the program to
control the exactness of the primer binding site
within the 16S rRNA sequences. The stringency
was first set to 100 per cent (E ¼ 10) to identify
the organisms that have exactly the same conserved
sequences as the primer and subsequently lowered
to E ¼ 5,000, which allowed a larger database to be
created as the conserved regions of the 16S rRNA
gene are not 100 per cent identical in sequence.
The resulting output shows the identity of all the
16S rRNA sequences that will produce an ampli-
con with a particular pair of primers, along with
the length(s) of the amplicons. Thus, one can
query the database using any primer to determine
the theoretical fragment lengths that would be gen-
erated from an organism when analysed. In
addition, a list of all bacteria that produce a specific
fragment length can be generated. One amplicon
length may represent more than one bacterium,
and thus only a presumptive identity of that ampli-
con can be achieved.
Results
PCR amplification of 16S rRNA genes
for metagenome profiling
Variable regions V1 and V1_V2 were successfully
amplified using universal eubacterial primers from
the metagenomic DNA samples (see Methods). As
expected, the amplicon sizes from the 19 samples
ranged from 335 to 365 bp for the V1_V2 region
(Table 1 and Supplementary Figure 1). Sample
UMC had the most complex V1_V2 profile, with
eight amplicons (Figure 1a and Table 1). Samples
UMF, UMG, UMH, UMJ, UMK, UMP and
UMT had the least complex LH profiles, with only
one amplicon present at 342 bp (Figure 1b and
Table 1). The remaining 11 samples produced LH
profiles containing multiple amplicons (Table 1 and
Supplementary Figure 1). Amplicon 342 was
observed in all 19 samples (Table 1). Out of these
19 samples, 16 samples (84.2 per cent) had ampli-
con 342 as the dominant member of the profile.
PRIMARY RESEARCH Doud et al.
150 # HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 4. NO. 3. 147–169 FEBRUARY 2010
Table 1: Amplicons seen in the V1 and V1_V2 regions for samples.
Sample V1_V2 (%)*† Total #
V1_V2
V1† Total # V1
UMA 342, 349 (39.0), 350 3 60, 62, 63, 65, 68, 69, 70, 72, 73, 75, 76, 77,
78, 81, 82, 83, 86 (17.3), 90, 91, 92, 93, 94,
96, 98, 100, 101, 108
27
UMB 342 (61.7), 347, 365 3 62, 63, 72, 73, 75, 76, 77, 78, 81, 82, 88
(15.7), 91, 93, 94, 98, 100, 102, 103, 112
19
UMC 335, 342 (79.0), 347, 349,
350, 351, 352, 365
8 61, 62, 68, 69, 70, 72, 73, 75, 76, 77, 78, 81,
82, 84, 86, 88 (12.0), 90, 91, 92, 93, 94, 96,
98, 100, 102, 104
26
UMD 342 (93.7), 351, 352, 365 4 64 (14.4), 70, 73, 77, 82, 86, 88, 98, 103, 112 10
UME 342 (99.0), 348 2 60, 62, 64, 66, 67, 68, 69, 71, 72 (12.3), 73,
74, 75, 76, 77, 78, 80, 81, 86, 88, 91, 93, 94,
98, 100, 102, 103, 112, 113, 115, 120
30
UMF 342 (100) 1 60, 61, 62, 65, 68, 70, 72 (12.6%), 73, 75, 77,
78, 85, 91, 93, 94, 98, 103, 112, 113, 115
20
UMG 342 (100) 1 60, 61, 62, 68, 72 (3.6), 73, 75, 77, 78, 86,
91, 93, 98, 103, 112, 113, 115, 119, 120
19
UMH 342 (100) 1 60, 61, 62, 65, 68, 70, 73, 75, 76, 77 (3.9),
78, 80, 81, 84, 85, 86, 88, 90, 91, 93, 94, 96,
98, 101, 103, 111, 112, 113, 115
29
UMJ 342 (100) 1 60, 61, 62, 63, 65, 68, 70, 72, 73, 75, 77, 78,
80, 81, 84, 86, 88, 91, 92, 93, 94, 98, 102
(6.6), 112, 113, 115, 120
27
UMK 342 (100) 1 60, 61, 62, 65, 67, 68, 70, 72, 73, 75, 77, 78,
81, 85, 86, 90, 91, 93, 94, 98, 100, 101 (7.3),
103, 111, 112, 113, 120
27
UML 342, 350, 360 (55.7), 365 4 60, 61, 62, 63, 64, 65, 67, 68, 70, 71, 72, 73,
76, 78, 81, 85, 88, 91, 94 (31.3), 98, 100,
102, 103, 112, 113, 115, 119, 120
28
UMM 342 (98.7), 351, 365 3 61, 62, 65, 68, 70, 73, 75, 76, 77, 78, 81, 82,
84, 86, 88, 91, 94, 98, 101 (4.8), 103, 111,
113, 115, 119, 120
25
UMN 339, 342 (92.7), 347, 352 4 60, 61, 62, 65, 68, 70 (10.2), 73, 77, 78, 81,
85, 86, 88, 90, 91, 92, 94, 98, 100, 103, 108,
112, 113, 115
24
UMO 342 (74.0), 350, 352 3 60, 62, 65, 73, 77, 78, 80, 81, 85, 91, 98, 102
(3.1), 103, 108, 111, 112, 113, 115, 119, 120
20
UMP 342 (100) 1 60, 61, 62, 65, 77, 78, 81, 98, 102 (5.7), 112,
115, 120
12
Continued
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The most abundant amplicons in UMA, UML and
UMR were 349, 360 and 360, respectively
(Table 1).
As predicted, V1 profiles ranged from 60 to
120 bp in length (Table 1 and Supplementary
Figure 2). Unlike V1_V2 profiles, all 19 samples
produced more diverse profiles containing multiple
amplicons in each profile (Table 1 and
Supplementary Figure 2). The most complex
profile contained 30 amplicons for UME (Figure 2
and Table 1). The least diverse profile with ten
amplicons belonged to UMD (Table 1 and
Supplementary Figure 2). All the samples contained
a 98 bp amplicon, although it was not the most
abundant amplicon (Table 1). The 86 bp amplicon
was present in ten out of the 19 profiles and was
the most dominant peak in UMA (17 per cent)
(Table 1). The 84 bp amplicon was found in five
profiles. Seventeen out of 19 samples contained a
73 bp amplicon.
Comparison of LH eubacterial profiles
within CF centre
The profiles for each sample were compared with
each other to determine if the bacterial commu-
nities were similar between patients that were
treated at the same CF centre. The normalised
abundance data from the V1_V2 region were ana-
lysed using the Bray–Curtis similarity index. The
similarity between samples was shown in a dendo-
graph using group linkage clustering. The UMF
profile had 100 per cent similarity to UMG,
UMH, UMJ, UMK, UMP and UMT as they all
produced 100 per cent abundance for amplicon
342 (Table 1 and Figure 3a). The UMR profile had
36.0 per cent or less similarity with 13 of the
Table 1: Continued
Sample V1_V2 (%)*† Total #
V1_V2
V1† Total # V1
UMQ 342 (41.3), 348, 350, 365 4 60, 61, 62, 63, 64, 65, 71, 72, 76, 78, 81, 84,
85, 87, 91, 94, 98, 102 (5.3), 103, 112, 115
21
UMR 342, 360 (63.7) 2 60, 62, 63, 65, 73, 77, 78, 80, 81, 82, 85, 94
(13.9), 98, 102, 108, 112, 115, 120
18
UMS 339, 342 (87.7), 347 3 60, 62, 63, 66, 72, 73, 74, 77, 78, 80, 81, 85,
88, 91, 94, 98, 102 (9.9), 103, 111, 112, 113,
115, 119, 120
24
UMT 342 (100) 1 60, 62, 63, 65, 71, 72, 73, 76, 78, 81, 85, 92,
94, 98, 102 (13.2), 111, 112, 115, 120
19
*The V1_V2 region ranges from 300–400 bp. The V1 region ranges from 60–120 bp.
†Amplicons in bold are the most abundant amplicon in the profile for that particular sample. The number in parenthesis indicates the percentage abundance of the dominant
amplicon for that region.
Figure 1. Hypervariable V1_V2 amplicon data graphs. Panel a
represents the V1_V2 profile from patient UMC. Panel b
depicts the profile obtained from patients UMF, UMG, UMH,
UMJ, UMK, UMP and UMTusing the V1_V2 region.
PRIMARY RESEARCH Doud et al.
152 # HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 4. NO. 3. 147–169 FEBRUARY 2010
samples, but had a 91.0 per cent similarity with
UML (Figure 3a). The UMR and UML profiles
had two amplicons in common. The V1 region
was able to discriminate between all samples; no
two profiles were exactly the same (Table 1 and
Figure 3b). The highest similarity between two
profiles was 79.2 per cent between UMF and
UMG due to the presence of many shared ampli-
cons (Figure 3b). The most dissimilar profiles were
those of UMD and UMQ, with just 6.2 per cent
similarity between them. Four out of the ten
amplicons were common between UMD and
UMQ (Table 1).
The similarity of the patients’ bacterial
population with both the V1_V2 and the V1 data
was also compared. The combination of
regions decreased the degree of similarity between
V1_V2 profiles, yet the LH profiles were most
dissimilar to the V1 region data (data not shown).
Patient CF flora changes over time
The lung flora changes over time in the CF lung.
It is also known that the composition of the bac-
terial community in the lung at any one time varies
due to the compartmentalised structure of the
organ.34 When working with expectorated sputum,
it was assumed that the bacterial community within
a given patient may vary from sample to sample. In
order to study the dynamics of lung flora over a
period of time, sampling bias was addressed — that
is, any changes seen in community profiles over
time may potentially be an artefact from the
sampling method. A control experiment was per-
formed to understand the effect of sampling.
Figure 2. Hypervariable V1 amplicon data. Graph depicts the V1 profile from patient UME, which was the most diverse profile found
in this study.
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Sputa samples from patient UML were analysed
over the course of two years (Month 1 to Month
22). The samples were referred to as M0, M3, M16,
M17, M22.1, M22.2, M22.3, M22.4 and M22.5.
Five samples were taken on the same day, every
three hours for 12 hours (M22.1–M22.5). The
sampling scheme was designed to account for the
potential variability contributed by the lung struc-
ture. All samples were analysed using the V1 and
V1_V2 regions. The Bray–Curtis similarity index
was used to determine the variation between the
community profiles of the patient samples. The
relatedness of bacterial communities was shown with
dendographs created from the calculated similarity
(Figure 4). In addition, the relationship between
profiles was graphically depicted using non-metric
MDS, which represents the samples as points in a
low-dimensional space, so that the relative distances
of the symbols is correlated with the same rank
order determined by the Bray–Curtis similarity
index (Figure 5). These analyses showed that samples
taken on the same day were more similar than LH
profiles from earlier time points (Figures 4 and 5).
For the V1_V2 region, the samples in M22 ranged
from 70.6 per cent to 93.4 per cent in similarity.
The first three samples M1, M3 and M16 had less
than 42.9 per cent similarity to any profile produced
from the hourly samples. The LH profile M17 and
the five profiles in M22 were related, with a range
of 52.8 per cent to 78.3 per cent similarity. M22.4
was more similar to M17 than the other same-day
samples (Figure 4a).
Figure 3. Similarity-based clustering between LH profiles of
patients. Panels a and b are dendographs indicating the
relatedness of LH profiles of patients generated from the
V1_V2 and V1 regions, respectively. Bray–Curtis similarity
index and group-linked clustering were used to determine
similarity of bacterial communities. Figure 4. Similarity-based clustering between LH profiles over
time in one patient (UML). Panels a and b are dendographs
indicating the relatedness of LH profiles from UML generated
from the V1_V2 and V1 regions, respectively. Panel c describes
the community similarity when both V1_V2 and V1 data are
combined. The Bray–Curtis similarity index and group-linked
clustering were used to determine similarity of bacterial
communities.
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The V1 profiles for these samples were also
analysed and compared. Overall, the similarities
between samplings were much lower when using
the V1 versus the V1_V2 region (Figures 4b and
5b). The highest profile similarities were seen
within M22 samples; similarities as high as 96.0 per
cent were seen between M22.3 and M22.5. M1
and M3 had a similarity of 48.1 per cent; M16 and
M17 were 47.1 per cent similar. Some of the sam-
plings taken months prior to the daily sampling in
M22 were completely different (Figure 4b). The
MDS analysis clearly showed that samples taken on
the same day (M22) clustered (Figure 5b).
Combining LH data from both the V1 and the
V1_V2 regions further indicated the overall simi-
larity of the bacterial community within one day
versus over a period of time (Figures 4c and 5c).
The additive effect of the regions created a tighter
clustering of the same-day samples and increased
distances between samples taken in different
months (Figure 4c).
Antibiotics drive the CF community
After the initial time study with patient UML, two
more patients were followed for a period of time
to determine the effect of antibiotics on the lung
microbial flora. Azithromycin, co-trimoxazole
(Bactrim), tobramycin and polymyxin E (Colistin)
were administered at different time points for each
patient. Azithromycin, which is most often used to
treat Gram-negative bacteria, is a macrolide anti-
biotic which interferes with protein synthesis, pre-
venting growth of bacteria.35 Co-trimoxazole
(Bactrim) is a combination of sulfamethoxazole and
trimethoprim and interferes with DNA synthesis in
bacteria that cause respiratory infections, especially
in Stenotrophomonas maltophilia.36,37 Tobraymcin, an
aminoglycoside, prevents translation in bacteria.
The inhaled form of the drug targets P. aeruginosa
in the lungs.38 Polymyxin E is effective against
most Gram-negative bacilli and is often used against
multidrug-resistant strains of P. aeruginosa.39 The
drug regime and sputa samples from two patients,
referred to as patient UMX and patient UMY, were
analysed every other month for five months. The
three time points are referred to as M0, M3 and
M5. The amplicons of size 60–120 bp and 300–
400 bp were obtained from the V1 and the V1_V2
regions, respectively (Table 2).
Patient UMX was under triple combination
therapy with azithromycin, co-trimoxazole
(Bactrim) and tobramycin at least two weeks prior
and up to the sampling at month 0 (M0) and
month 3 (M3). Two weeks prior to month 5 (M5),
the patient stopped taking tobramycin but
Figure 5. Similarity between LH profiles over time in one
patient. Panels a and b are MDS figures which represent the
profiles generated from patient UML over a period of time
using the V1_V2 and V1 regions, respectively. Panel c is the
MDS figure representing the combined V1_V2 and V1 data.
Blue diamond, blue pentagon, red heart, red diamond, orange
cross, green triangle, black hexagon, aqua square and purple
circle represent samples from Month 1, Month 3, Month 16,
Month 17, Month 22.1–22.5, respectively.
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Table 2: Amplicon contributions for Patients UMX and UMYover a five-month time period.
Patient UMX Patient UMY
Amplicon
(bp)*
M0a (%) M3a (%) M5b (%) Amplicon
(bp)*
M0c (%) M3d (%) M5d (%)
Unique amplicons
352 P (2.34) P (13.00)
351 P (1.67)
348 348 P (1.00) P (33.88)
347 347 P (35.33)
120 P (1.88) P (5.88) 120
119 P (1.88) P (3.53) 119
113 P (3.77) P (2.35) 113
111 P (3.53) 111
108 P (18.82) 108
100 100 P (4.66)
94 94 P (0.99) P (0.81) P (1.85)
87 87 P (2.47)
84 84 P (1.23)
76 76 P (1.84) P (1.63) P (4.94)
74 74 P (0.81)
71 71 P (4.07) P (6.79)
70 P (4.36) 70
69 69 P (0.81)
67 67 P (0.81)
66 66 P (0.81)
65 65 P (3.70)
63 63 P (3.25) P (3.09)
Shared amplicons
342 P (93.67) P (100) P (74.00) 342 P (61.67) P (99.00) P (34.16)
365 P (2.00) 365 P (3.00) P (2.20)
350 P (13.00) 350 P (29.75)
115 P (3.77) P (2.35) 115 P (0.81) P (2.47)
112 P (16.50) P (3.77) P (4.71) 112 P (10.31) P (0.81) P (3.09)
Continued
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continued treatment with azyithromycin and co-
trimoxazole (Bactrim). The number of amplicons
for the V1_V2 and V1 LH profiles varied for the
three time points (Table 2). The dominant 342 bp
amplicon was present at each time point (93.7 per
cent, 100 per cent and 74 per cent at M0, M3, and
M5, respectively) for the V1_V2 region (Table 2).
The dominant amplicons in V1 for M0, M3 and
M5 were those with 64 (21.4 per cent), 72 (20.8
per cent) and 108 (18.8 per cent) bp, respectively.
For the V1 profile, amplicons with 73, 77, 103 and
112 bp were present at all time points. Amplicons
with 64, 70, 82, 88, 351 and 365 bp were present
only during M0. The 352 bp amplicon was found
Table 2: Continued
Patient UMX Patient UMY
Amplicon
(bp)*
M0a (%) M3a (%) M5b (%) Amplicon
(bp)*
M0c (%) M3d (%) M5d (%)
103 P (4.85) P (9.43) P (5.88) 103 P (2.68) P (1.23)
102 P (10.59) 102 P (8.62) P (3.25) P (29.63)
98 P (5.66) P (8.24) 98 P (6.92) P (6.50) P (3.70)
93 P (3.77) 93 P (0.99) P (0.81)
91 P (3.77) P (4.71) 91 P (3.53) P (1.63) P (2.47)
88 P (12.13) 88 P (19.92) P (1.63)
86 P (1.88) 86 P (13.01)
85 P (7.06) 85 P (6.79)
82 P (14.07) 82 P (2.97)
81 P (1.18) 81 P (2.12) P (3.25) P (3.70)
80 P (1.18) 80 P (2.44)
78 P (3.77) P (1.18) 78 P (1.69) P (3.25) P (1.85)
77 P (8.73) P (3.77) P (5.88) 77 P (4.24) P (1.63)
75 P (1.88) 75 P (2.26) P (2.44)
73 P (8.73) P (3.77) P (3.53) 73 P (2.26) P (3.25)
72 P (20.75) 72 P (1.27) P (30.08) P (11.73)
68 P (3.77) 68 P (0.81)
64 P (21.35) 64 P (0.81) P (1.23)
62 P (3.77) P (4.71) 62 P (18.79) P (1.63) P (2.47)
61 P (3.77) 61 P (1.23)
60 P (15.09) P (4.71) 60 P (12.20) P (3.70)
*V1_V2 amplicons range from 300–400 bp whereas V1 amplicons range from 60–120 bp.
M0, M3 and M5 refers to collection of samples at time 0, three and five months
P indicates presence of amplicon with its percentage abundance in the individual profile for that specific region.
aPatient UMX was treated with azithromycin, co-trimoxazole and tobramycin
bPatient UMX was treated with co-trimoxazole
cPatient UMY was treated with levofloxacin (Levaquin)
dPatient UMY was treated with polymyxin E
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during M0, was absent in M3 and was present
again at M5. Amplicons with 61, 68, 72, 75, 86
and 93 bp were only present during M3.
Amplicons with 60, 62, 78, 91, 98, 113, 115, 119
and 120 bp appeared at M3 and were also detected
at M5. M5 unique amplicons had 80, 81, 85, 102,
108, 111 and 350 bp.
Patient UMY was taking levofloxacin for two
weeks prior to the M0 sampling. At least two
weeks prior to the second sampling (M3), the
therapy was changed to colistin. The LH profiles
(number and abundance) varied over time
(Table 2). The 342 bp amplicon in the V1_V2
region was the most abundant, with 61.7 per cent
at M0 and 99.0 per cent at M3; however, this
amplicon was drastically decreased at M5 (34.2 per
cent) (Table 2). The V1 amplicons with 62, 72, 76,
78, 81, 91, 94, 98, 102 and 112 bp were found at
all three time points. The amplicons with 63, 103
and 365 bp were present in M0 and M5 but absent
in M3. Amplicons unique to M0 had 82, 100 and
347 bp. Amplicons present at M0 and M3 but
absent in M5 had 73, 75, 77, 88 and 93 bp. M3
and M5 shared amplicons with 60, 64, 71 and
115 bp. The six unique amplicons present in M5
had 61, 65, 84, 85, 87 and 350 bp (Table 2).
Presumptive identity analysis
Based on amplicon lengths for both the V1_V2 and
V1 regions, separately or combined, a presumptive
identity for an organism can be determined. In an
attempt to achieve identification of an amplicon,
chromosomal DNA from several CF-related patho-
gens was amplified using V1_V2 primers and V1
primers. All strains of P. aeruginosa used in this study
amplified a 342 and an 83 bp amplicon for the
V1_V2 and V1 regions, respectively.
Stenotrophomonas maltophilia amplified a 350 and an
87 bp amplicon for the V1_V2 and V1 regions,
respectively. A 353 bp amplicon was generated for
Staphylococcus aureus for the V1_V2 region; however,
V1 primers amplified two peaks at 77 and 88 bp for
S. aureus. B. cenocepacia produced a 339 bp and an
85 bp amplicon for V1_V2 and V1, respectively.
Many LH profiles contained amplicons that corre-
spond to these bacterial isolates’ fragment sizes.
Nineteen LH V1_V2 profiles may have contained the
pathogen P. aeruginosa but only one sample contained
the corresponding V1 amplicon (83 bp) (Table 1). Five
samples had the 350 bp amplicon, which may be from
Stenotrophomonas maltophilia, but only one sample had
the corresponding V1 amplicon. None of the samples
had the Staphylococcus aureus-specific V1_V2 fragment
of 353 bp; however, the V1-specific fragments (77/88)
were present in 16 samples; nine of these samples con-
tained both fragments. The 339 and 85 bp amplicons,
which may correspond to B. cenocepacia, were present
in two and ten samples, respectively. Two samples con-
tained both amplicons.
The theoretical amplicon lengths for bacteria were
determined manually using in silico analysis and
AmpliQue´ and then compared with the LH profiles
of the strains. The manual in silico analysis deter-
mined the V1_V2 fragment length for one specific
strain of a CF pathogen. These results agreed with
the experimental data. The AmpliQue´ program was
developed to determine the V1_V2 fragment lengths
for all bacterial strains which had a 16S rRNA
sequence in Ribosomal Database Project II (RDPII).
The data generated from the program agreed with
the experimental data for some strains, yet showed
different fragments for other strains. For example, in
the database, some strains of Stenotrophomonas malto-
philia produced the same 350 bp fragment as our LH
result. In addition, many more fragment lengths
(304–344 and 346–351 bp) were identified for
various strains of Stenotrophomonas maltophilia. Various
isolates of P. aeruginosa produced theoretical fragments
ranging from 337–345 bp. Only two fragments,
347 bp and 348 bp, were produced for this region
based on H. influenzae sequences. AmpliQue´ deter-
mined that different isolates of Staphylococcus aureus
have a V1_V2 of 340–344 and 346–351 bp. Based
on B. cenocepacia sequences, any of the lengths 327,
335, 337, 338, 340, 344 or 346 bp fragments could
be generated using the bacterial primers. Most bac-
terial species produced multiple hits for the V1_V2
region (data not shown).
AmpliQue´ was unable to determine the fragment
sizes for many CF-related pathogens, including
PRIMARY RESEARCH Doud et al.
158 # HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 4. NO. 3. 147–169 FEBRUARY 2010
P. aeruginosa. In silico analysis was able to determine
the fragment lengths of CF pathogens, as the site of
primer binding could be detected manually. Again,
fragment lengths generated from sequences of indi-
vidual strains varied from the actual LH results for
the specific control strain. Four different isolates of P.
aeruginosa produced an 86 bp fragment for the V1
region, while experimentally the region was 83 bp
long. Some strains of Stenotrophomonas maltophilia
produced the same 87 bp fragment as the control
strain, while others were determined to have a frag-
ment of 85 or 88 bp in length. Staphylococcus aureus
strains were 91 bp long in that region, but the test
strain did not produce this fragment. The fragment
from B. cenocepacia was three bp longer (88 bp) than
the LH isolate’s profile (85 bp).
Discussion
LH analysis of 16S rRNA genes has been used to
detect both known and novel organisms that may
be present in many complex microbial commu-
nities, including sputa from CF patients.18,20,21,26
In these previous studies, only one region of
the 16S rRNA was used to identify bacteria
present in the community at one time point.18,26
Identification based on one region is difficult, and
it is hypothesised that the use of multiple regions
might provide more information about the com-
munity. In this study, the V1 and V1_V2 regions
(separately and combined) were analysed with
LH-PCR to determine the diversity and dynamics
of the CF lung. Identification of the most abundant
amplicon lengths in the LH profiles was attempted
through in silico analysis and AmpliQue´, a newly
designed bioinformatics program. Lastly, the
dynamics of the eubacterial community in the
sputum over a period of time was further studied
using data generated from the LH profiles.
The V1 region of the 16S rRNA gene
provides a more detailed look at the complex
bacterial community in the CF lung
The 16S rRNA gene contains nine variable regions.
In this study, the V1 region and the V1_V2 regions
were used to produce bacterial LH profiles of the
CF sputa samples (Table 1). The V1_V2 profiles
were identical for seven patients and hence were
unable to discriminate between patients. The 342 bp
amplicon produced a high relative fluorescence in
the electropherograms, which may have caused the
less dominant amplicons to be below the threshold
limit and inadvertently ignored (Table 1). PCR
amplification bias may also have decreased the detec-
tion of other bacteria that were less abundant than
the organism(s) represented by the 342 bp amplicon.
Therefore, it appeared that seven CF samples had
identical bacterial communities. Statistically, the
V1_V2 profiles cannot discriminate between patients
at the UM centre (Figure 3a). The V1 LH profiles
were more complex, and statically discriminated
between samples to a higher degree than the V1_V2
region (Figure 3). The V1 profiles which were
unique to each patient contained multiple amplicons
per sample (Table 1).
The use of multiple regions to increase discrimi-
nation between samples was not beneficial. The
identical communities shown in the V1_V2 profiles
negated the discriminatory power of the V1 region
when analysed in conjunction with each other.
The discriminatory strength of the V1 region, as
compared with the V1_V2 region, was also evident
in a soil community LH study.25 Prior LH analysis
on CF sputa used only the V1_V2 region, and
more information may have been gained by using
the V1 region.18 Using the profiles from the two
regions together did not differentiate profiles to the
same extent as the V1 region. The combinatorial
approach may be of more use in amplicon identifi-
cation or observing community dynamics.
CF patients harbour diverse bacterial
communities
The 19 sputum samples obtained from South
Florida patients produced unique profiles. No two
LH profiles for the V1 region were the same
(Table 1 and Figure 3b). The V1_V2 region profiles
all contained an amplicon of length 342 bp, which
presumptively could be identified as Pseudomonas
species, Burkholderia species (but not B. cenocepacia)
or Ralstonia species. The 342 bp amplicon is indica-
tive of P. aeruginosa, since control CF isolates
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produced a fragment of this size. In addition, the
patients were clinically diagnosed with P. aeruginosa.
The high relative fluorescence of the 342 bp ampli-
con also indicated a severe infection, which would
be in agreement with culturing results. The intense
fluorescence of the fragment in seven samples may
have skewed the community profile, causing it to
appear as if there was only one type of bacteria
present. The V1 region for these seven samples
show some shared amplicons, but largely they had
very diverse microbial communities. Although
some amplicons (presence of, not abundance) are
common to patients, no two overall profiles were
identical to each other (Table 1 and Figure 3b).
It was thought that there are only a few patho-
gens commonly found in the lungs of CF patients,
due to clinical diagnostic procedures.40 Molecular
techniques have revealed that many more organisms
plague the CF lung, which is in agreement with
our findings.17,18 Many of the samples in this study
produced LH profiles that contained numerous
amplicons, some in low abundance. These less
dominant amplicons may represent bacteria that are
not routinely cultured and are potentially respon-
sible for some of the differences seen in disease
manifestation between CF patients with the same
genetic mutations. Recent Sanger sequencing pro-
jects have identified uncultured bacteria in the CF
lung.11,17 Deeper sequencing techniques, such as
454, could be used to identify other, less abundant
and potentially uncultured organisms.41 In order to
understand the significance of these organisms
within the CF lung, proper statistical tools for com-
parative metagenomics need to be developed.
Challenges of identifying organisms in
complex communities
One of the downsides to the LH technique is that
the organism found in a sample cannot be conclu-
sively identified. We hypothesised that organisms
could be presumptively identified based on the
V1_V2 and V1 amplicon lengths that would be
generated from LH-PCR. In this study, the frag-
ment lengths for both regions were experimentally
determined for one strain of four known CF patho-
gens. In addition, in silico analysis and AmpliQue´
were used to determine the expected amplicon
length of a variable region for any given organism.
This information was correlated with the LH
profile in an attempt to identify the bacteria present
in the CF sputum. The bioinformatics approach
highlighted the presence of intra-species length
variation present in both regions. The high degree
of variation seen in different isolates drastically
decreased the ability to identify a bacteria based on
the length of one hypervariable region. It was pre-
viously known that one amplicon length could rep-
resent multiple species, thereby allowing only a
presumptive identification. Based on the absence of
a peak, a specific genus or species could be ruled
out from being a member of the community. The
AmpliQue´ output clearly demonstrates that one
V1_V2 fragment could represent a multitude of
species or genera. The wide range of fragment
lengths generated for different isolates of the species
may be accurate or it may be due to problems
related to the database used in the program. The
database contains sequences which are determined
by various users. It is possible that some of the
length heterogeneity at the isolate level may arise
from poor sequencing reads, incorrect trimming of
sequences, and old taxonomy references (some
organism names have changed). Database issues will
change as more genome-wide sequencing is per-
formed. As it stands currently, identification is
nearly impossible based solely on amplicon length
from the V1_V2 region.
The V1 region, which was more informative
when looking at the community profile as a whole,
proved to be more problematic when analysing
individual peaks. Chromosomal DNA of P. aerugi-
nosa, Staphylococcus aureus, Stenotrophomonas maltophi-
lia and B. cenocepacia were amplified using the V1
primers and the fragment lengths were detected. In
silico analysis was used to determine fragment
lengths for the CF-associated lung pathogens,
including those listed above (although not always
the same isolate). The initial analysis indicated the
presence of length heterogeneity within species.
AmpliQue´ was used to determine the degree of
strain variation present in the V1 region. The
primer binding parameter was initially set to 100
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per cent stringency, which resulted in a very small
database of organisms and their corresponding frag-
ment lengths. Many CF pathogens, including P. aer-
uginosa, were not present at this high stringency. By
lowering the stringency, AmpliQue´ generated more
results, yet no information was given for P. aerugi-
nosa. The V1 region primers (P1F and P2R) exper-
imentally amplified P. aeruginosa PAO1. To
determine the putative primer binding site, the 16S
rRNA sequence for PAO1 was manually examined.
Both the forward and reverse primer sequences
show some degeneracy. Lowering the stringency
parameter was unable to correct for this degeneracy.
This issue can be resolved by determining the
binding motif of the primers using programs such
as iterative enhancement of motifs (IEM)42 and
then using that motif in AmpliQue´. Although P1F
is a common V1 primer used extensively in the
laboratory, other, less degenerate V1 forward
primers, such as 27F (which was used to amplify
V1_V2), could be used when attempting to ident-
ify organisms based on amplicon length. Selection
of primers for LH-PCR is critical to ensure that all
bacteria are being amplified and to increase the
success of identification based on fragment length.
The widely used primers, 27F and 355R, are based
on Escherichia coli sequence and should be thought
of as generalised primers and not universal
primers.43 Primers that have been developed with a
bioinformatics approach may prove to be more
useful in future LH studies.43
Due to the limitations of the V1 AmpliQue´ data-
base, identification using two regions simultaneously
could not be performed. Therefore, identification
based on two regions has yet to be proven. Further
modification of AmpliQue´ and/or the use of differ-
ent primers or variable regions may eventually lead
to LH-PCR being used as an identification tech-
nique. At this time, LH-PCR can still be useful
when looking at a bacterial community as a whole.
The eubacterial communities in CF
lungs are dynamic
The LH-PCR profiles provided a view of the CF
bacterial community as a whole. It is known that in
soil and water samples, the members of a community
and their abundances change, and these changes
can be driven by external factors.44,45 Thus, it is
hypothesised that the bacterial community within
the CF lung also changes based on external factors.
To understand the changes in the community,
LH-PCR was used to profile three patients over a
period of time. Samples from patient UML were
used to determine the bacterial community vari-
ation over a short period of time (three hours) and
over a long period of time (two years). Samples
from patients UMY and UMX were used to study
how antibiotics may affect the lung community.
Sputum samples from patient UML were ana-
lysed over the course of two years (M0, M3, M16,
M17, M22.1, M22.2, M22.3, M22.4 and M22.5).
Five samples were taken on the same day, every
three hours for 12 hours (M22.1–M22.5). For
both the V1 and the V1_V2 LH profiles, the
overall bacterial community was more similar
within the one day than across multiple time
periods over two years (Figures 4 and 5). The LH
profiles from the samples taken in one day were not
identical. These variations may arise from transient
bacteria that were present in the oral cavity at the
time of sampling (such as Lactobacillus from yogurt).
Analysing the samples with both regions further
demonstrated that bacterial communities change
over time. By combining regions, the data indi-
cated increased similarity of the samples taken in
one day, which was due to the more abundant
organisms, not the less dominant amplicons in the
profile that may represent the transient bacteria in
the oral community. The dissimilarity between the
samples taken months apart was increased due to
the presence of the more dominant, possibly
disease-causing, organisms (Figures 4c and 5c).
This LH analysis is the first to show that colonisa-
tion of the CF lung is dynamic and that these
changes can be tracked.
To date, the dynamics of the bacterial commu-
nity in the CF lung in response to external drivers
such as the presence of antibiotics has yet to be
studied. Thus, a short-term study was performed in
an attempt to understand how the overall commu-
nity in the lung changes when under attack by anti-
biotics. To begin, CF sputum samples from patient
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UMX and patient UMY were analysed every other
month for five months. During this time, patients
were taking a combination of antibiotics.
During the five-month period, patient UMX was
taking azithromycin, co-trimoxazole and tobramycin.
Shortly before the third time point, the patient
stopped taking tobramycin. The patient’s profiles
contained a large number of V1 amplicons, whose
presence and abundance changed throughout the
time course (Table 2). For V1_V2, patient UMX’s
profiles consisted predominantly of amplicon 342 at
all time points (Table 2). This fragment was pre-
sumptively identified as P. aeruginosa, which con-
curred with the patient’s clinical diagnosis.
Interestingly, UMX had been prescribed tobramycin
(which targets P. aeruginosa) for the majority of the
sampling period, yet the 342 bp amplicon was always
present in large abundance (74–100 per cent). LH
analysis with both the V1 and V1_V2 regions indi-
cated a dynamic environment within the lungs of
UMX. These changes seen over the time period are
likely to be an effect of the antibiotic regime.
Patient UMY’s profile was more dynamic than
that of patient UMX. Patient UMY’s sputum
showed a high level of abundance for the 342 bp
amplicon between the first two samplings, followed
by a drastic decrease in the abundance of the
342 bp amplicon in the profile from the third
sampling (Table 2). This change in profile may cor-
respond to the patient’s antibiotic regime poly-
myxin E specifically, replacing levofloxacin. This
may have caused the pathogen associated with that
amplicon to disappear. As the abundance of the
342 bp amplicon decreased, a 348 bp amplicon
emerged. It is possible that as one pathogen was
cleared, it was replaced with another bacterium that
fitted that niche.46 The decreasing 342 bp amplicon
may represent P. aeruginosa, which had been cul-
tured from the patient. Levofloxacin and polymyxin
E are both used to target against this pathogen.
There are studies that have demonstrated that levo-
floxacin is less effective in treating P. aeruginosa than
the first-generation fluoroquinolones.47 Antibiotic-
resistant strains of P. aeruginosa are often treated with
polymyxin E.48,49 It could be hypothesised that
patient UMY was infected with an antibiotic-
resistant strain of P. aeruginosa which may have been
susceptible to the stronger antibiotic. The patient’s
lung infection was then dominated by a bacterium
represented by the 348 bp amplicon, which may
belong to H. influenzae or Stenotrophomonas malto-
philia. Changes in the bacterial community were
also seen in the V1 profiles (Table 2). Due to the
limitations of AmpliQue´, it is not clear if similar
changes in abundance were seen in peaks that may
represent P. aeruginosa.
The microbial community was more dynamic in
UMY, a 60-year-old Caucasian man, than in UMX,
a 23-year-old Hispanic woman. The number of
unique amplicons in UMX and UMY were eight
and 14, respectively. UMX had five (73, 77, 103,
112 and 342 bp) and UMY had 11 (62, 72, 76, 78,
81, 91, 94, 98, 102, 112 and 342 bp) amplicons that
were present at all three time points. These constant
amplicons may come from chronic colonisers that
no longer respond to the treatment regimen. The
uniqueness, diversity and selective abundance of
certain amplicons could be attributed to the age,
gender and ethnicity. The patients’ respective lung
flora may have adapted to their immune response
and the presence of antibiotics differently. The vari-
ations in profiles due to age and antibiotic treatment
have been previously demonstrated.5,50
Clearly, LH can be used to analyse changes in a
microbial community. Although this study used a
small sample size over a relatively short period of
time, changes in the presence and abundance of
amplicons in the LH profiles could be seen. To
identify the drivers of the community accurately, a
more comprehensive long-term study needs to be
performed. Armed with the patient’s antibiotic
information and long-term sampling, it should be
possible to determine the effectiveness of a drug
against pathogens in the CF lung. This could even-
tually lead to more effective treatments.
In conclusion, LH-PCR analysis detected the
dynamic and complex flora that is present in South
Florida CF patients. Although LH-PCR could not
be used to identify bacteria in this study, it still proved
to be a useful community profiling technique.
LH-PCR of the V1_V2 and, to a greater extent, the
V1 region of the 16S rRNA gene can be used to
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compare microbial communities between samples.
Interpreting LH profiles may provide insight into the
evolution of a microbial community and identify the
factors that drive these changes. Technologies such as
pyrosequencing will probably be used to identify the
members present in the bacterial community;
however, LH-PCR is still an accessible tool that can
be implemented to study microbial communities.
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Supplementary Figure 1. Hypervariable region V1_V2 amplicon data graphs. Panels a–e represent patients UMA–UME. Panels f– i
refer to patients UML, UMM, UMN and UMO, respectively. Panels j, k and l represent patients UMQ, UMR and UMS, respectively.
Panel m represents profiles from patients UMF, UMG, UMH, UMJ, UMK and UMT. Continued
Combination of 16S rRNA variable regions provides a detailed analysis of bacterial community dynamics PRIMARY RESEARCH
# HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 4. NO 3. 147–169 FEBRUARY 2010 165
Supplementary Figure 1.
PRIMARY RESEARCH Doud et al.
166 # HENRY STEWART PUBLICATIONS 1479–7364. HUMAN GENOMICS. VOL 4. NO. 3. 147–169 FEBRUARY 2010
Supplementary Figure 2. Hypervariable region V1 amplicon data graphs. Panels a–h are the graphs for patients UMA–UMH,
respectively. Panels i–s refer to patients UMJ–UMT, respectively. Continued
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